Tagged News
Bevacizumab Benefits in Colorectal Cancer Limited to Two-Year Window, New Analysis Reveals
• A comprehensive review presented at the 2025 ASCO Gastrointestinal Cancers Symposium reveals bevacizumab (Avastin) provides survival benefits in colorectal cancer patients for approximately two years after initial administration.
• Researchers found that after 20-24 months, the initial survival benefit from bevacizumab diminishes, potentially explaining the crossover of survival curves observed in the PARADIGM trial compared to panitumumab (Vectibix).
• The study suggests bevacizumab treatment may lead to selection of more aggressive tumor clones over time, characterized by accelerated growth and invasiveness after the initial period of tumor stasis and shrinkage.
Related Clinical Trials:
Hoffmann-La Roche
Posted 12/1/2004
National Cancer Institute (NCI)
Posted 9/15/2004
Alliance for Clinical Trials in Oncology
Posted 11/1/2005
PD Dr. med. Volker Heinemann
Posted 1/1/2007
Takeda
Posted 5/29/2015
CytomX Therapeutics Initiates Combination Therapy Arm in Phase 1 Melanoma Trial
• CytomX Therapeutics has dosed the first patient in a combination arm studying CX-801 with Keytruda (pembrolizumab) for patients with metastatic melanoma.
• The Phase 1 trial aims to evaluate safety, tolerability, and preliminary efficacy of this novel combination approach targeting advanced melanoma patients.
• This study represents a significant step in exploring how CX-801's mechanism may potentially enhance the effectiveness of established immunotherapy treatments.
Doxorubicin Plus Pembrolizumab Shows Promise in Phase 2 Trial for Advanced Soft Tissue Sarcoma
• A Phase 2 trial evaluating the combination of doxorubicin and pembrolizumab demonstrated encouraging efficacy and manageable safety profile in patients with advanced soft tissue sarcoma.
• The study reported significant objective response rates and disease control, potentially offering a new treatment approach for this challenging malignancy with limited therapeutic options.
• Researchers presented these findings at the recent American Society of Clinical Oncology (ASCO) meeting, highlighting the potential of immunotherapy combinations in sarcoma treatment.
SystImmune to Present Updated Izalontamab Brengitecan Data for HER2-Negative Breast Cancer at ESMO Breast 2025
• SystImmune will present updated Phase 1 data on izalontamab brengitecan (iza-bren), a novel EGFRxHER3 bispecific antibody-drug conjugate, at ESMO Breast Cancer 2025 in Munich, Germany.
• The data shows encouraging efficacy across all HER2 levels in HER2-negative breast cancer patients, including HER2 0 patients, building on previously reported results at SABCS 2024.
• Iza-bren, jointly developed by SystImmune and Bristol Myers Squibb, demonstrates strong clinical efficacy with a manageable safety profile, potentially addressing significant unmet needs in breast cancer treatment.
Yuhan's Lung Cancer Drug Leclaza Secures European Approval in Combination Therapy
• Yuhan Corporation's third-generation EGFR-TKI lazertinib (Leclaza) has received European Commission approval in combination with J&J's Rybrevant for first-line treatment of EGFR-mutated non-small cell lung cancer.
• The Phase 3 MARIPOSA study demonstrated the combination therapy reduced disease progression risk by 30% compared to osimertinib, with median progression-free survival of 23.7 months versus 16.6 months.
• This milestone marks the first Korean anticancer drug approved in both the U.S. and Europe, triggering a $30 million payment to Yuhan as part of their $1.255 billion licensing deal with Johnson & Johnson.
FDA Approves Tevimbra-Chemotherapy Combination for First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma
• The FDA has approved BeiGene's Tevimbra (tislelizumab-jsgr) in combination with platinum-containing chemotherapy for first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.
• In the pivotal RATIONALE-306 trial, patients treated with Tevimbra plus chemotherapy demonstrated a median overall survival of 16.8 months compared to 9.6 months with chemotherapy alone, representing a 34% reduction in risk of death.
• This marks BeiGene's third FDA approval in less than a year, following previous approvals for Tevimbra in second-line ESCC and first-line gastric/gastroesophageal junction cancers, highlighting the company's expanding oncology portfolio.
Related Clinical Trials:
BeiGene
Posted 1/26/2018
BeiGene
Posted 7/22/2019
Endevica Bio Advances TCMCB07 to Phase 2 Trial for Preventing Chemotherapy-Induced Weight Loss
• Endevica Bio has received FDA authorization to begin a Phase 2 clinical trial of TCMCB07 (B07), a peptide designed to prevent weight loss in stage 4 metastatic colorectal cancer patients undergoing chemotherapy.
• The trial will enroll 100 patients who will receive B07 before and during chemotherapy, targeting cachexia - a life-threatening wasting syndrome affecting millions of cancer patients worldwide.
• TCMCB07, a melanocortin-3/4 antagonist peptide, has shown promising results in Phase 1 trials and preclinical studies, demonstrating its ability to preserve lean muscle mass and improve appetite in cancer treatment settings.
PeproMene Bio Secures $11 Million Investment to Advance BAFF-R CAR T-Cell Therapy for Follicular Lymphoma
• PeproMene Bio has received an $11 million investment from the Institute for Follicular Lymphoma Innovation to develop PMB-CT01, a novel BAFF-R CAR T-cell therapy for relapsed/refractory follicular lymphoma.
• Early clinical results show promising efficacy with a 100% complete response rate in six non-Hodgkin lymphoma patients and minimal side effects, including in patients who relapsed after CD19 CAR T-cell therapy.
• PMB-CT01 targets the BAFF-R receptor, which is crucial for B-cell survival, potentially making it difficult for tumor cells to escape therapy through antigen loss, a common limitation of current CD19-targeted therapies.
Related Clinical Trials:
PeproMene Bio, Inc.
Posted 5/18/2021
PeproMene Bio, Inc.
Posted 6/13/2022
AI Support Significantly Improves HER2 Scoring Accuracy in Breast Cancer Diagnosis
• A new study published in JCO Precision Oncology demonstrates that Ibex Medical Analytics' AI technology significantly improves pathologists' accuracy and consistency in HER2 biomarker scoring for breast cancer.
• The multi-center study showed AI-assisted pathologists achieved higher inter-observer agreement (83.7% vs 75%) and improved accuracy in identifying challenging HER2-low cases, which is critical for determining eligibility for new targeted therapies.
• The "zero-click" decision support tool demonstrated exceptional robustness across multiple labs, antibodies, scanners, and patient demographics, offering particular value in distinguishing between HER2 0 and 1+ cases.
Daiichi Sankyo and Merck Expand Collaboration to Develop Novel DLL3-Targeting T-Cell Engager for Small Cell Lung Cancer
• Daiichi Sankyo and Merck have expanded their existing partnership to include MK-6070, an investigational DLL3-targeting T-cell engager, with Merck receiving $170 million upfront in the agreement.
• MK-6070 targets delta-like ligand 3 (DLL3), which is highly expressed in small cell lung cancer and neuroendocrine tumors, and has received FDA Orphan Drug Designation for SCLC treatment.
• The companies plan to evaluate MK-6070 in combination with ifinatamab deruxtecan (I-DXd) in patients with small cell lung cancer, addressing an aggressive cancer with significant unmet treatment needs.
Related Clinical Trials:
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Posted 12/14/2020